Optimizing therapeutic antibody function: progress with Fc domain engineering.

Abstract excerpt

Since the establishment of monoclonal antibody production using hybridoma technology in the mid-1970s, there has been expanding progress and continuous technological improvement in the development of therapeutic antibodies. The initial technological breakthroughs involved reduction of immunogenicity and thus enabled repeated administration. The establishment of chimeric, humanized, and fully human antibodies has...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal
• Share to Histocompatibility Antigens Class I